Actively Recruiting
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Led by Inova Health Care Services · Updated on 2025-10-07
19
Participants Needed
2
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
CONDITIONS
Official Title
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- Newly diagnosed and previously untreated hepatocellular carcinoma confirmed by biopsy or imaging with at least one measurable lesion
- Cancer must be locally advanced and unresectable
- Childs-Pugh cirrhosis score of A5 or A6
- Eastern Cooperative Oncology Group Performance Status of 0-1
- Adequate bone marrow and organ function including neutrophil count ≥ 1,500/µL, platelets ≥ 100,000/µL, hemoglobin ≥ 90 g/L, bilirubin ≤ 3 times upper limit of normal, liver enzymes ≤ 3 times upper limit of normal (or ≤ 5 times if due to tumor), creatinine ≤ 2.0 mg/dL, and eGFR > 40 ml/min
- Agreement to use effective contraception for sexually active participants with partners of childbearing potential
- Ability to understand and willingness to sign informed consent
- Men and women of all races, ethnic groups, and sexual orientations
- Ability to swallow oral medication
You will not qualify if you...
- Childs-Pugh B or C cirrhosis
- Female patients who are pregnant or breastfeeding
- Concomitant illnesses preventing adequate assessment or posing added risk
- History or evidence of severe illness or uncontrolled infections such as HIV, HBV, or HCV
- Enrollment in another interventional clinical trial
- Active tuberculosis
- Significant cardiovascular disease within 3 months prior to study treatment
- History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins
- Known hypersensitivity to components of atezolizumab or bevacizumab
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Uncontrolled tumor-related pain or unstable pain medication regimen
- Major surgery, open biopsy, or significant injury within 28 days prior to treatment
- Symptomatic, untreated, or progressing central nervous system metastases
- Active, untreated grade 2 or 3 varices (treated grade 1 or less allowed)
- Prior use of memantine before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Inova Schar Cancer Institute - Fair Oaks
Fairfax, Virginia, United States, 22033
Actively Recruiting
2
Inova Health Care Service
Falls Church, Virginia, United States, 22042
Actively Recruiting
Research Team
K
Keary Jane't
CONTACT
E
Elahe Mollapour
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here